Biocon Biologics receives European Commission approval for biosimilar of Aflibercept ‘Yesafili’
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway